3 active not recruiting, 3 completed, 2 not yet recruiting, 1 recruiting. 11 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Active not recruiting 3, Completed 3, Not yet recruiting 2, Recruiting 1, Suspended 1, Terminated 1 |
| Phase 1 | 1 | Suspended 1 |
Follow 2-Propanol: new trials by email Literature Review of 2-Propanol trials Research Report on 2-Propanol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer Isopropyl Alcohol, Placebo, Questionnaire Administration - Malignant Neoplasm | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 112 | 2026-11-05 | 2026-05-27 |
| Propranolol Treatment for Postoperative Chylothorax Propranolol Hydrochloride, Placebo - Postoperative Chylothorax, Congenital Heart Disease | Phase 1 / Phase 2 | Suspended | June Wu | 50 | 2025-09-09 | 2026-05-15 |
| Cleaning the Biopsy Needle in TRUS Bx Isopropyl Alcohol, Povidine-iodine, formaldehit - Prostatic Cancer | Phase 2 | Not yet recruiting | Hitit University | 200 | 2025-03-01 | 2025-02-20 |
| Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 1 | 2023-08-14 | 2026-01-09 |
| Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation Enasidenib Mesylate - Acute Myeloid Leukemia | Phase 2 | Active not recruiting | City of Hope Medical Center | 35 | 2019-12-23 | 2026-11-10 |
| CPX-351 Plus Enasidenib for Relapsed AML Enasidenib Mesylate, Liposome-encapsulated Daunorubicin-Cytarabine - Recurrent Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 2 | 2019-04-12 | 2023-09-28 |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Azacitidine, Enasidenib Mesylate - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2018-09-18 | 2026-09-14 |
| In Vivo Preoperative Skin Preparation Efficacy Study Within a Defined Product Coverage Area 3M CHG/IPA Prep - Surgical Skin Preparation, Surgical Procedure, Unspecified | Phase 2 | Completed | Solventum US LLC | 28 | 2017-06-06 | 2024-10-02 |
| In Vivo Preoperative Skin Preparation Persistence Evaluation 3M CHG/IPA Prep, ChloraPrep - Bacterial Recovery of Skin Flora Post-product Application | Phase 2 | Completed | Solventum US LLC | 69 | 2016-12-05 | 2024-10-02 |
| Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™ Chloraprep, ZuraPrep, ZuraPrep Vehicle - Surgical Site Infection | Phase 2 | Terminated | Zurex Pharma, Inc. | 64 | 2014-08-01 | 2016-07-18 |
| Efficacy of JUC as Hand Rub Evaluated by Using European Standard 1500 JUC solution, propan-2-ol - Infectious Disease Transmission | Phase 2 | Completed | The Hong Kong Polytechnic University | 15 | 2012-06-01 | 2014-12-11 |
Leukemia, Myeloid, Acute (4) · Chylothorax (1) · Heart Defects, Congenital (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Prostatic Neoplasms (1) · Sepsis (1) · Surgical Wound Infection (1)
M.D. Anderson Cancer Center (2) · Solventum US LLC (2) · Children's Oncology Group (1) · City of Hope Medical Center (1) · Hitit University (1) · Jonsson Comprehensive Cancer Center (1) · June Wu (1) · The Hong Kong Polytechnic University (1) · Zurex Pharma, Inc. (1)
United States (7) · Canada (1) · Hong Kong (1) · Romania (1)
Rozalia Olsavszky, MD (2) · Amandeep Salhotra (1) · Caspian Oliai, MD (1) · Chris Beausoleil (1) · Courtney DiNardo (1) · John Yuen, PhD (1) · June Wu, MD (1) · Sara Zarnegar-Lumley (1) · Yvonne J Heung (1)
PMID 33394722, PMID 35078972, PMID 42369177
U10CA180886 (1)